Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study

Next Previous
Trial Profile

Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bosentan (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Acronyms COMPASS-2
  • Sponsors Actelion Pharmaceuticals

Most Recent Events

  • 24 May 2023 Results of meta analysis (n=1982 from 3 studies NCT01106014 , NCT00660179 and NCT00303459) assessing Outcomes in Patients With Pulmonary Arterial Hypertension (PAH) Associated With Congenital Heart Disease (CHD) Receiving PAH Medication presented at the 119th International Conference of the American Thoracic Society
  • 23 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 25 Mar 2014 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top